Assetmark Inc. increased its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 5.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,491 shares of the company’s stock after buying an additional 354 shares during the period. Assetmark Inc.’s holdings in VanEck Pharmaceutical ETF were worth $617,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Optimum Investment Advisors acquired a new stake in VanEck Pharmaceutical ETF in the second quarter worth about $27,000. GPS Wealth Strategies Group LLC acquired a new position in VanEck Pharmaceutical ETF in the second quarter valued at approximately $42,000. CWM LLC acquired a new position in VanEck Pharmaceutical ETF in the second quarter valued at approximately $55,000. International Assets Investment Management LLC purchased a new stake in shares of VanEck Pharmaceutical ETF in the second quarter valued at approximately $86,000. Finally, Comerica Bank increased its position in shares of VanEck Pharmaceutical ETF by 39.4% during the first quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after purchasing an additional 378 shares in the last quarter.
VanEck Pharmaceutical ETF Stock Performance
Shares of PPH opened at $86.59 on Friday. VanEck Pharmaceutical ETF has a one year low of $76.39 and a one year high of $99.51. The stock has a market capitalization of $639.90 million, a price-to-earnings ratio of 21.04 and a beta of 0.72. The stock has a 50 day moving average price of $93.68 and a 200 day moving average price of $92.98.
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- What Is WallStreetBets and What Stocks Are They Targeting?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Why Are Stock Sectors Important to Successful Investing?
- Top-Performing Non-Leveraged ETFs This Year
- When to Sell a Stock for Profit or Loss
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
